Researchers engineer self-assembling micelles for drug delivery

Nanowerk News gives us an update on micelles, which are nanoparticles with a core-shell structure. Like many nanoparticles that are potential vehicles for targeted drug delivery, they come with a drawback: they can only carry a small amount of a drug and can dissociate quickly in the bloodstream when they come into contact with proteins. Researchers from A*STAR Institute of Bioengineering and Nanotechnology in Singapore and from the IBM Almaden Research Center say they have found a way around this problem: a polymer that self-assembles into micelles with high loading capacity and stability in the body.

"There are micelles that can transport large amounts of drugs, but their synthesis is usually tedious, expensive and gives low yields," A*STAR researcher Yiyan Yang said in a news release. "We have now developed an approach to produce biodegradable and biocompatible polycarbonate copolymers that form uniformly sized micelles in high yields from inexpensive starting materials. Furthermore, the synthesis can be scaled up for future clinical applications."

When the researchers tested the micelles for drug delivery in vitro, they steadily released doxorubin to cancer cells, killing them efficiently. The next step is a search for collaborators as they conduct animal studies.

- read the report in Nanowerk News

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

Suggested Articles

Iowa State University is working on a room-temp-stable nasal spray vaccine for COVID-19, and it recently tapped device maker Zeteo for support.

ApiJect systems snared a $590 million from the U.S. government to build a multi-facility campus to crank out more than 3 billion injectors per year.

A team at the University of New South Wales Sydney developed a light-activated liposome that could deliver CRISPR treatments with fewer side effects.